WO2004108114B1 - Composition antifongique et son procede de fabrication - Google Patents

Composition antifongique et son procede de fabrication

Info

Publication number
WO2004108114B1
WO2004108114B1 PCT/IN2004/000076 IN2004000076W WO2004108114B1 WO 2004108114 B1 WO2004108114 B1 WO 2004108114B1 IN 2004000076 W IN2004000076 W IN 2004000076W WO 2004108114 B1 WO2004108114 B1 WO 2004108114B1
Authority
WO
WIPO (PCT)
Prior art keywords
dichlorophenyl
fungal
methyl
imidazole
methoxy
Prior art date
Application number
PCT/IN2004/000076
Other languages
English (en)
Other versions
WO2004108114A2 (fr
WO2004108114A3 (fr
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Original Assignee
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani filed Critical Dinesh Shantilal Patel
Publication of WO2004108114A2 publication Critical patent/WO2004108114A2/fr
Publication of WO2004108114A3 publication Critical patent/WO2004108114A3/fr
Publication of WO2004108114B1 publication Critical patent/WO2004108114B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant au moins un agent antifongique choisi dans le groupe imidazoles, triazoles, allylamines, leurs dérivés et polyènes, divers composés tels que hydroxy pyridones comme 2,5(1'S,6'R)-7-chloro-2',-4,6-triméthoxy-6'-méthylspiro[benzofurane-2(3H),1'-[2]cyclohexène]-3,4'-dione et acide carbamothioïque-méthyl(3-méthylphényl) O-2-naphthalényl ester, en particulier, α-(2,4-Difluorophényl)- α-(1H-1,2,4-triazole-1-ylméthyl)-1H-1,2,4-triazole-1-éthanol et N-[(2E)-6,6-Diméthyl-2-hepten-4-ynyl]-N-méthyl-1-naphthalène-méthanamine hydrochlorure dans un support sélectif de 2,5-di-O-méthyl-1,4:3,6-dianhydro-D-glucitol et ses dérivés. La préparation est appropriée pour administration par voies parentérale, orale et locale. La préparation en solution peut être administrée directement ou utilisée pour fabriquer des comprimés, des suspensions, des gouttes, des formulations de vernis à ongles et analogues.
PCT/IN2004/000076 2003-03-31 2004-03-31 Composition antifongique et son procede de fabrication WO2004108114A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN49MU2003 2003-03-31
IN49/MUM/2003 2003-03-31

Publications (3)

Publication Number Publication Date
WO2004108114A2 WO2004108114A2 (fr) 2004-12-16
WO2004108114A3 WO2004108114A3 (fr) 2005-10-06
WO2004108114B1 true WO2004108114B1 (fr) 2005-11-17

Family

ID=33495852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000076 WO2004108114A2 (fr) 2003-03-31 2004-03-31 Composition antifongique et son procede de fabrication

Country Status (1)

Country Link
WO (1) WO2004108114A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US4912124A (en) * 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
DE3600947A1 (de) * 1986-01-15 1987-07-16 Kali Chemie Pharma Gmbh Antimykotische emulsionen
US4711904A (en) * 1986-08-04 1987-12-08 Luzzi Louis A Method of treating skin disorders
EP0270316A3 (fr) * 1986-12-04 1989-12-06 Pfizer Inc. Compositions topiques contenant des imidazoles 1-substitués et des agents non-steroides anti-inflammatoires pour le traitement de l'acné
DE69023654T2 (de) * 1989-08-25 1996-04-18 Bioglan Ireland R & D Ltd Pharmazeutische zusammensetzung und einnahmevorrichtung dafür.
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
ATE138561T1 (de) * 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
FR2740685B1 (fr) * 1995-11-08 1998-01-23 Pf Medicament Composition pharmaceutique topique moussante pour le traitement des dermatoses, induites par pityrosporum ovale

Also Published As

Publication number Publication date
WO2004108114A2 (fr) 2004-12-16
WO2004108114A3 (fr) 2005-10-06

Similar Documents

Publication Publication Date Title
Rani et al. Imidazoles as potential antifungal agents: A review
DE59400216D1 (de) Fungizide Mischungen
CA2388320A1 (fr) Derives carbamoyloxyalkyl-azolium n-substitues
JP2002521400A5 (fr)
HUP9901620A2 (hu) Itrakonazolt tartalmazó gombaellenes készítmények
CA2252677A1 (fr) Melange fongicide
KR910021398A (ko) 트리아졸 항진균제
KR890006593A (ko) 아르마타제 억제4(5)- 이미다졸
CA2149733A1 (fr) Microbiocides
IE840463L (en) Imidazoles and triazoles
NO986087L (no) Oralt preparat omfattende en antifungal triazolforbindelse
FI62836B (fi) Foerfarande foer framstaellning av heterocykliska derivat av bakterier och svampar foerstoerande 1-(1,3-dioxolan-2-ylmetyl)-1h-imidazoler och -1h-1,2,4-triazoler
US4782059A (en) Method of controlling mycotic infections and compositions therefor
JP2001526187A5 (fr)
ES2223893T3 (es) Combinaciones de productos activos fungicidas.
US20170290810A1 (en) Anti-fungal compositions for treating nails and methods for fabricating and using thereof
SK285763B6 (sk) Azol, spôsob jeho prípravy a medziprodukt na jehoprípravu, jeho použitie a farmaceutický prostriedok s jeho obsahom
WO2004108114B1 (fr) Composition antifongique et son procede de fabrication
RU97116580A (ru) Триазоловое соединение и его фармакологически приемлемая соль и противогрибковая композиция
US20020193384A1 (en) Use of azoles for the preventing skin cancer
KR950030794A (ko) 식물 처리 방법
JPH0233016B2 (fr)
Mishra et al. Chemistry and pharmacology of luliconazole (imidazole derivative): a novel bioactive compound to treat fungal infection-a mini review
GB2234170A (en) Fungicidal compositions containing antibiotic ¼-lactone and a synergistic azole
RU97115756A (ru) Производные n-бензилазолия

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050923

122 Ep: pct application non-entry in european phase